LEKTI Antibody (E-9): sc-137109

LEKTI Antibody (E-9) is a mouse monoclonal IgG2a kappa light chain antibody that detects LEKTI protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). LEKTI (E-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The lympho-epithelial Kazal-type inhibitor (LEKTI) plays a crucial role as a serine protease inhibitor, providing essential protection to mucous epithelia against microbial invasion and inflammation, which is vital for maintaining the integrity of epithelial barriers. LEKTI is predominantly located in the granular and uppermost spinous layers of the epidermis, as well as in the differentiated layers of stratified epithelia, highlighting LEKTI′s importance in epithelial differentiation and function. Notably, mutations in the SPINK5 gene, which encodes LEKTI, are linked to Netherton syndrome, a severe autosomal recessive disorder characterized by atopic dermatitis, hay fever, and other related conditions, underscoring LEKTI′s significance in skin health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LEKTI Antibody (E-9) References:

1. LEKTI, a novel 15-domain type of human serine proteinase inhibitor.  |  Mägert, HJ., et al. 1999. J Biol Chem. 274: 21499-502. PMID: 10419450
2. LEKTI: a multidomain serine proteinase inhibitor with pathophysiological relevance.  |  Mägert, HJ., et al. 2002. Int J Biochem Cell Biol. 34: 573-6. PMID: 11943586
3. Biochemical features, molecular biology and clinical relevance of the human 15-domain serine proteinase inhibitor LEKTI.  |  Walden, M., et al. 2002. Biol Chem. 383: 1139-41. PMID: 12437098
4. Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis.  |  Mitsudo, K., et al. 2003. Biochemistry. 42: 3874-81. PMID: 12667078
5. Homologous proteins with different folds: the three-dimensional structures of domains 1 and 6 of the multiple Kazal-type inhibitor LEKTI.  |  Lauber, T., et al. 2003. J Mol Biol. 328: 205-19. PMID: 12684009
6. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.  |  Bitoun, E., et al. 2003. Hum Mol Genet. 12: 2417-30. PMID: 12915442
7. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases.  |  Raghunath, M., et al. 2004. J Invest Dermatol. 123: 474-83. PMID: 15304086
8. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome.  |  Hachem, JP., et al. 2006. J Invest Dermatol. 126: 1609-21. PMID: 16601670
9. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins.  |  Di, WL., et al. 2009. Br J Dermatol. 161: 404-12. PMID: 19438860
10. Keratinocyte-specific mesotrypsin contributes to the desquamation process via kallikrein activation and LEKTI degradation.  |  Miyai, M., et al. 2014. J Invest Dermatol. 134: 1665-1674. PMID: 24390132
11. Incomplete KLK7 Secretion and Upregulated LEKTI Expression Underlie Hyperkeratotic Stratum Corneum in Atopic Dermatitis.  |  Igawa, S., et al. 2017. J Invest Dermatol. 137: 449-456. PMID: 27769847
12. MiR-375-3p alleviates the severity of inflammation through targeting YAP1/LEKTI pathway in HaCaT cells.  |  Cheng, S., et al. 2020. Biosci Biotechnol Biochem. 84: 2005-2013. PMID: 32564679

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-LEKTI Antibody (E-9) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-LEKTI Antibody (E-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

LEKTI Antibody (E-9) Specifications

Alternate Product Name: LEKTI

Product Clone Name: E-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 261-560

Epitope Target: LEKTI

Epitope Species: human

Product Reactivity/Detection: LEKTI precursor and mature form and HF7665 active peptide

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for LEKTI Antibody (E-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin